DCTH

Delcath Systems, Inc.

7.99 USD
+0.21 (+2.70%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Delcath Systems, Inc. stock is up 53.36% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 43.48% of the previous 22 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 May 19:50 17 May, 2024 2.50 CALL 106 705
16 May 15:25 16 Aug, 2024 5.00 CALL 177 444

About Delcath Systems, Inc.

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.

  • HC Wainwright & Co.
    Wed May 15, 06:50
    buy
    confirm
  • Stephens & Co.
    Tue May 14, 05:43
    buy
    initial